CN101331122B - Ppar调节剂的盐和治疗代谢性疾病的方法 - Google Patents

Ppar调节剂的盐和治疗代谢性疾病的方法 Download PDF

Info

Publication number
CN101331122B
CN101331122B CN2006800398402A CN200680039840A CN101331122B CN 101331122 B CN101331122 B CN 101331122B CN 2006800398402 A CN2006800398402 A CN 2006800398402A CN 200680039840 A CN200680039840 A CN 200680039840A CN 101331122 B CN101331122 B CN 101331122B
Authority
CN
China
Prior art keywords
ppar
compound
salt
group
term
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2006800398402A
Other languages
English (en)
Chinese (zh)
Other versions
CN101331122A (zh
Inventor
S·D·帕伦特
D·T·约奈蒂斯
D·A·贝内特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kalypsys Inc
Original Assignee
Kalypsys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kalypsys Inc filed Critical Kalypsys Inc
Publication of CN101331122A publication Critical patent/CN101331122A/zh
Application granted granted Critical
Publication of CN101331122B publication Critical patent/CN101331122B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN2006800398402A 2005-10-25 2006-10-23 Ppar调节剂的盐和治疗代谢性疾病的方法 Expired - Fee Related CN101331122B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US73024905P 2005-10-25 2005-10-25
US60/730,249 2005-10-25
PCT/US2006/060172 WO2007051095A1 (en) 2005-10-25 2006-10-23 Salts of modulators of ppar and methods of treating metabolic disorders

Publications (2)

Publication Number Publication Date
CN101331122A CN101331122A (zh) 2008-12-24
CN101331122B true CN101331122B (zh) 2011-09-07

Family

ID=37770916

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2006800398402A Expired - Fee Related CN101331122B (zh) 2005-10-25 2006-10-23 Ppar调节剂的盐和治疗代谢性疾病的方法

Country Status (14)

Country Link
US (1) US7863276B2 (enExample)
EP (1) EP1940815B1 (enExample)
JP (2) JP5322650B2 (enExample)
KR (1) KR101464767B1 (enExample)
CN (1) CN101331122B (enExample)
AU (1) AU2006305769B2 (enExample)
BR (1) BRPI0619282B8 (enExample)
CA (1) CA2624383C (enExample)
DK (1) DK1940815T3 (enExample)
ES (1) ES2691548T3 (enExample)
HU (1) HUE040020T2 (enExample)
IL (1) IL190396A (enExample)
NZ (1) NZ566831A (enExample)
WO (1) WO2007051095A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2384576C2 (ru) * 2004-10-29 2010-03-20 Калипсис, Инк Сульфонил-замещенные бициклические соединения в качестве модуляторов ppar
AR060937A1 (es) * 2006-05-16 2008-07-23 Kalypsys Inc Compuestos biciclicos sustituidos con sulfonilo como moduladores de ppar
US20080004281A1 (en) * 2006-06-28 2008-01-03 Kalypsys, Inc. Methods for the modulation of crp by the selective modulation of ppar delta
WO2008091863A1 (en) 2007-01-23 2008-07-31 Kalypsys, Inc. Sulfonyl-substituted bicyclic compounds as ppar modulators for the treatment of non-alcoholic steatohepatitis
US20220331267A1 (en) * 2019-09-05 2022-10-20 Rush University Medical Center Methods and compositions for treatment of demyelinating disorders

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4237130A (en) * 1979-06-21 1980-12-02 Merck & Co., Inc. 2,3-Dihydro-6,7-disubstituted-5-(substituted sulfonyl)benzofuran-2-carboxylic acids
US4600709A (en) * 1982-10-22 1986-07-15 Ciba-Geigy Ag Benzodioxole derivatives, processes for the manufacture thereof and corresponding pharmaceutical compositions
CN85107226A (zh) * 1984-09-05 1987-04-08 盐野义制药株式会社 2，3-二氢苯并呋喃-5-磺酰胺衍生物的制备方法
CA1223874A (en) * 1982-10-22 1987-07-07 Paul Zbinden Benzodioxole derivatives, processes for the manufacture thereof and corresponding pharmaceutical compositions
CN1402712A (zh) * 1999-12-03 2003-03-12 京都药品工业株式会社 新的杂环化合物及其盐和它们的医药用途
WO2004092117A1 (en) * 2003-04-07 2004-10-28 Kalypsys, Inc. Para-sulfonyl substituted phenyl compounds as modulators of ppars
WO2005016881A1 (de) * 2003-08-02 2005-02-24 Bayer Healthcare Ag Bicyclische indolinsulfonamid-derivate
WO2006055187A1 (en) * 2004-10-29 2006-05-26 Kalypsys, Inc. Sulfonyl-substituted bicyclic compounds as modulators of ppar

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0158596A3 (de) * 1984-04-06 1986-08-13 Ciba-Geigy Ag Neue substituierte Benzodioxolderivate, Verfahren zu deren Herstellung und entsprechende pharmazeutische Zusammensetzungen
JPS6163671A (ja) 1984-09-05 1986-04-01 Shionogi & Co Ltd ２，３−ジヒドロベンゾフラン−５−スルホンアミド誘導体および降圧利尿剤
JPH05255089A (ja) 1991-12-18 1993-10-05 Sanwa Kagaku Kenkyusho Co Ltd 抗ウイルス剤
US5464788A (en) * 1994-03-24 1995-11-07 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
GB9600464D0 (en) 1996-01-09 1996-03-13 Smithkline Beecham Plc Novel method
JP2002507192A (ja) 1997-06-17 2002-03-05 シェーリング コーポレイション ファルネシルタンパク質トランスフェラーゼの新規三環式スルホンアミドインヒビター
YU47600A (sh) 1998-01-27 2002-09-19 Aventis Pharmaceuticals Products Inc. SUPSTITUISANI OKSOAZAHETEROCIKLIL INHIBITORI FAKTORA Xa
US7517884B2 (en) * 1998-03-30 2009-04-14 Kalypsys Inc. Sulfonyl-substituted bicyclic compounds as modulators of PPAR
CA2342251A1 (en) 1998-08-28 2000-03-09 Scios Inc. Use of piperidines and/or piperazines as inhibitors of p38-alpha kinase
WO2000017163A1 (en) * 1998-09-22 2000-03-30 Yamanouchi Pharmaceutical Co., Ltd. Cyanophenyl derivatives
JP2003525203A (ja) 1999-03-22 2003-08-26 ダーウィン・ディスカバリー・リミテッド ヒドロキサムおよびカルボン酸誘導体
JP2001261657A (ja) 2000-03-17 2001-09-26 Yamanouchi Pharmaceut Co Ltd シアノフェニル誘導体
GB0007907D0 (en) 2000-03-31 2000-05-17 Merck Sharp & Dohme Therapeutic agents
EP2292593A3 (en) * 2000-09-29 2011-05-25 TopoTarget UK Limited Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors
US20040180925A1 (en) * 2000-12-27 2004-09-16 Kenji Matsuno Dipeptidylpeptidase-IV inhibitor
CN100457726C (zh) 2001-06-11 2009-02-04 比奥维特罗姆股份公开公司 取代的磺酰胺化合物、其制备方法及其作为治疗cns疾病、肥胖和ⅱ型糖尿病的药物的应用
US7456184B2 (en) * 2003-05-01 2008-11-25 Palatin Technologies Inc. Melanocortin receptor-specific compounds
NZ536116A (en) 2002-04-03 2007-01-26 Topotarget Uk Ltd Carbamic acid compounds comprising a piperazine linkage as HDAC inhibitors
US6875780B2 (en) * 2002-04-05 2005-04-05 Warner-Lambert Company Compounds that modulate PPAR activity and methods for their preparation
CN1181065C (zh) * 2002-05-08 2004-12-22 上海医药工业研究院 芳烷甲酰烷基哌嗪衍生物及其作为脑神经保护剂的应用
AU2003237532B2 (en) * 2002-06-12 2009-07-30 Symphony Evolution, Inc. Human ADAM-10 inhibitors
CN1751037A (zh) 2003-02-14 2006-03-22 伊莱利利公司 作为ppar调节剂的磺酰胺衍生物
CA2521135A1 (en) 2003-04-07 2004-10-28 Kalypsys, Inc. N-containing heteroaromatic compounds as modulators of ppars and methods of treating metabolic disorders
CN1791409A (zh) 2003-04-17 2006-06-21 凯利普西斯公司 作为 p p a r调节剂的 ( 3 －{ 3'－ [ ( 2 , 4 －双 －三氟甲基 －苄基)－ ( 5 －乙基 －嘧啶 － 2 －基 )－氨基 ]－丙氧基} －苯基) －乙酸及相关化合物以及治疗代谢失调的方法
WO2005011654A2 (en) 2003-07-29 2005-02-10 Xenon Pharmaceuticals Inc. Pyridyl derivatives and their use as therapeutic agents
ES2397389T3 (es) 2003-07-30 2013-03-06 Xenon Pharmaceuticals Inc. Derivados de piridilo y su uso como agentes terapéuticos
KR20060037409A (ko) 2003-07-30 2006-05-03 제논 파마슈티칼스 인크. 피페라진 유도체 및 그의 치료제로서의 용도
KR20060037410A (ko) 2003-07-30 2006-05-03 제논 파마슈티칼스 인크. 피리다진 유도체 및 그의 치료제로서의 용도
US20050124625A1 (en) 2003-10-21 2005-06-09 Salvati Mark E. Piperazine derivatives and their use as modulators of nuclear hormone receptor function
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
WO2005060958A1 (en) 2003-12-19 2005-07-07 Kalypsys, Inc. (5- (2-phenyl)-thiazol-5-ylmethoxy)-indol-1-yl) -acetic acid derivatives and related compounds as modulators of the human ppar-delta receptor for the treatment of metabolic disorders such as type 2 diabetes
AR048523A1 (es) 2004-04-07 2006-05-03 Kalypsys Inc Compuestos con estructura de aril sulfonamida y sulfonilo como moduladores de ppar y metodos para tratar trastornos metabolicos
BRPI0418939A (pt) 2004-07-06 2008-04-08 Xenon Pharmaceuticals Inc derivados de nicotinamida e sua utilização como agentes terapêuticos
EP2289510A1 (en) 2004-09-20 2011-03-02 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes
CA2580856A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
US7767677B2 (en) 2004-09-20 2010-08-03 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
JP4958787B2 (ja) 2004-09-20 2012-06-20 ゼノン・ファーマシューティカルズ・インコーポレイテッド ヒトステアロイル−ＣｏＡデサチュラーゼを阻害するためのピリジン誘導体
US7951805B2 (en) 2004-09-20 2011-05-31 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase
EP2316458A1 (en) 2004-09-20 2011-05-04 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase
EP1799667B1 (en) 2004-09-20 2013-03-20 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as therapeutic agents
CN101083986A (zh) 2004-09-20 2007-12-05 泽农医药公司 双环杂环衍生物及其作为硬脂酰CoA去饱和酶(SCD)抑制剂的用途
US20070190079A1 (en) * 2004-10-29 2007-08-16 Kalypsys, Inc. Methods for the selective modulation of ppar
US20090143396A1 (en) * 2005-10-12 2009-06-04 Malecha James W Sulfonyl-Substituted Aryl Compounds as Modulators of Peroxisome Proliferator Activated Receptors
WO2007047432A1 (en) 2005-10-12 2007-04-26 Kalypsys, Inc. Sulfonamide derivatives as modulators of ppar
WO2007109577A1 (en) * 2006-03-17 2007-09-27 Kalypsys, Inc. Alkylamine-substituted bicyclic aryl compounds useful as modulators of ppar
US20070249519A1 (en) * 2006-04-20 2007-10-25 Kalypsys, Inc. Methods for the upregulation of glut4 via modulation of ppar delta in adipose tissue and for the treatment of disease
US20080004281A1 (en) * 2006-06-28 2008-01-03 Kalypsys, Inc. Methods for the modulation of crp by the selective modulation of ppar delta
WO2008043024A2 (en) 2006-10-04 2008-04-10 Kalypsys, Inc. Oral pharmaceutical formulation comprising a sulfonyl bicyclic modulator of ppar for the treatment of disease
US20080287477A1 (en) * 2006-10-11 2008-11-20 Kalypsys, Inc. Novel Compounds as Modulators of Ppar
WO2008091863A1 (en) * 2007-01-23 2008-07-31 Kalypsys, Inc. Sulfonyl-substituted bicyclic compounds as ppar modulators for the treatment of non-alcoholic steatohepatitis

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4237130A (en) * 1979-06-21 1980-12-02 Merck & Co., Inc. 2,3-Dihydro-6,7-disubstituted-5-(substituted sulfonyl)benzofuran-2-carboxylic acids
US4600709A (en) * 1982-10-22 1986-07-15 Ciba-Geigy Ag Benzodioxole derivatives, processes for the manufacture thereof and corresponding pharmaceutical compositions
CA1223874A (en) * 1982-10-22 1987-07-07 Paul Zbinden Benzodioxole derivatives, processes for the manufacture thereof and corresponding pharmaceutical compositions
CN85107226A (zh) * 1984-09-05 1987-04-08 盐野义制药株式会社 2，3-二氢苯并呋喃-5-磺酰胺衍生物的制备方法
CN1402712A (zh) * 1999-12-03 2003-03-12 京都药品工业株式会社 新的杂环化合物及其盐和它们的医药用途
WO2004092117A1 (en) * 2003-04-07 2004-10-28 Kalypsys, Inc. Para-sulfonyl substituted phenyl compounds as modulators of ppars
WO2005016881A1 (de) * 2003-08-02 2005-02-24 Bayer Healthcare Ag Bicyclische indolinsulfonamid-derivate
WO2006055187A1 (en) * 2004-10-29 2006-05-26 Kalypsys, Inc. Sulfonyl-substituted bicyclic compounds as modulators of ppar

Also Published As

Publication number Publication date
EP1940815B1 (en) 2018-08-15
IL190396A (en) 2017-09-28
IL190396A0 (en) 2008-11-03
JP2013166788A (ja) 2013-08-29
CA2624383C (en) 2014-03-11
DK1940815T3 (en) 2018-11-05
KR101464767B1 (ko) 2014-11-24
CN101331122A (zh) 2008-12-24
NZ566831A (en) 2011-09-30
KR20080059575A (ko) 2008-06-30
JP5322650B2 (ja) 2013-10-23
BRPI0619282A2 (pt) 2011-09-20
CA2624383A1 (en) 2007-05-03
ES2691548T3 (es) 2018-11-27
US20070093504A1 (en) 2007-04-26
AU2006305769B2 (en) 2012-06-14
AU2006305769A1 (en) 2007-05-03
BRPI0619282B8 (pt) 2021-05-25
US7863276B2 (en) 2011-01-04
JP2009513679A (ja) 2009-04-02
HUE040020T2 (hu) 2019-02-28
BRPI0619282B1 (pt) 2021-05-04
WO2007051095A1 (en) 2007-05-03
EP1940815A1 (en) 2008-07-09

Similar Documents

Publication Publication Date Title
CA2465326C (en) Pyrazolopyrimidines for decreasing ion flow through a voltage-dependent sodium channel
TWI304062B (en) N-(pyridin-2-yl)-sulfonamide derivatives
RU2706007C2 (ru) Конденсированные бициклические соединения для лечения заболевания
WO2001083427A1 (en) PPARη MODULATORS
KR20010113972A (ko) 융합 복소환 화합물의 염산염
CN105121423A (zh) 新型3-(4-(苄氧基)苯基)己-4-炔酸衍生物、其制备方法、和包括其作为有效成分的用于预防和治疗代谢性疾病的药物组合物
Zhang et al. Design, synthesis, and bioevaluation of novel NLRP3 inhibitor with IBD immunotherapy from the virtual screen
JP2013166788A (ja) Ｐｐａｒ調節剤の塩および代謝障害の治療方法
JP2511204B2 (ja) 置換インド―ル
CN107602523A (zh) 京尼平类似物、制备方法及其应用
CN108348525A (zh) 羟基嘌呤类化合物的医药用途
CN115974839B (zh) AChE/SERT双靶点抑制剂及其制备方法和用途
CN101397300A (zh) 二肽酶-ⅳ抑制剂衍生物
TW202421620A (zh) 馬拉利習巴(maralixibat)固體形式、中間體及其製備方法
KR20230121762A (ko) (5s)-사이클로프로필-5-[3-[(3s)-4-(3,5-디플루오로페닐)-3-메틸-피페라진-1-일]-3-옥소-프로필]이미다졸리딘-2,4-디온의 고체 형태
WO2024027751A1 (zh) 一种杂环化合物的晶型、其制备方法及其应用
TW202543619A (zh) Ｒｘｆｐ１受體促效劑
KR20250065708A (ko) 타우 응집 억제제
CN116723840A (zh) (5s)-环丙基-5-[3-[(3s)-4-(3,5-二氟苯基)-3-甲基-哌嗪-1-基]-3-氧代-丙基]咪唑烷-2,4-二酮的固体形式
WO2021168341A1 (en) Solid forms of 1-(5-(3-(7-(3-fluorophenyl)-3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)-n,n-dimethylmethanamine
WO2021023119A1 (zh) 美利曲辛与氟哌噻吨共晶及其制备方法
CN102076682A (zh) 五元环化合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20110907

CF01 Termination of patent right due to non-payment of annual fee